Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Chloroprocaine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A known ✓ | P35498 | 5/20 | 0.66 |
| ▸ | SCN2A known ✓ | Q99250 | 5/20 | 0.66 |
| ▸ | SCN3A known ✓ | Q9NY46 | 5/20 | 0.66 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.97 |
| ▸ | HTR3A | P46098 | 3/20 | 0.97 |
| ▸ | MAOA | P21397 | 3/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.97 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.97 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.97 |
| ▸ | HTR2C | P28335 | 1/20 | 0.97 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.66 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 4/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chloroprocaine SCHEMBL1650786 | 1.00 | HRH3 (0.97) | HRH3HTR3AMAOAKCNH2CHRM2 | |
| Chloroprocaine SCHEMBL6676 | 0.99 | HRH3 (1.00) | HRH3HTR3AMAOAKCNH2CHRM2 | |
| Chloroprocaine SCHEMBL29354179 | 0.99 | HRH3 (1.00) | HRH3HTR3AMAOAKCNH2CHRM2 | |
| Chloroprocaine SCHEMBL21612249 | 0.97 | HRH3 (0.97) | HRH3HTR3AMAOAKCNH2CHRM2 | |
| Chloroprocaine SCHEMBL28104711 | 0.93 | HRH3 (0.88) | HRH3HTR3AMAOAKCNH2CHRM2 | |
| Chloroprocaine SCHEMBL6272449 | 0.92 | HRH3 (0.86) | HRH3HTR3AMAOAKCNH2CHRM2 | |
| SCHEMBL13440006 | 0.90 | HRH3 (0.84) | HRH3HTR3AMAOAKCNH2CHRM2 | |
| Chloroprocaine SCHEMBL2471312 | 0.90 | MAOA (0.82) | HRH3HTR3AMAOAKCNH2CHRM2 | |
| Chloroprocaine SCHEMBL3808985 | 0.89 | HRH3 (0.80) | HRH3HTR3AMAOAKCNH2CHRM2 | |
| SCHEMBL13440004 | 0.87 | HTR3A (0.79) | HRH3HTR3AMAOAKCNH2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1952 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260097044-A1 | ION PAIR LIQUID CRYSTAL FORMULATIONS FOR LONG-ACTING INJECTABLES OF POORLY SOLUBLE DRUGS | FORDOZ PHARMA CORP. (US) | 2026-04-09 | — | — | US | claimed |
| US-20250269093-A1 | METHODS OF ENHANCING ANTIMICROBIAL EFFICACY OF LOCAL ANESTHETICS | Chinook Contract Research Inc. (CA) | 2025-08-28 | — | — | US | claimed |
| CN-119738515-A | Method for simultaneously determining 6 benzoic acid genotoxic impurities in chloroprocaine hydrochloride or preparation thereof by adopting ESI-LC-MSMS technology | 南京清科医药科技有限公司 | 2025-04-01 | — | — | CN | claimed |
| CN-119707723-A | Preparation method of chloroprocaine hydrochloride | 浙江昂利泰制药有限公司 | 2025-03-28 | — | — | CN | claimed |
| WO-2025015419-A1 | METHODS OF ENHANCING ANTIMICROBIAL EFFICACY OF LOCAL ANESTHETICS | Chinook Contract Research Inc. (CA) | 2025-01-23 | — | — | WO | claimed |
| CN-119241383-A | Efficient synthesis method of chloroprocaine hydrochloride | 南京斯泰尔医药科技有限公司 | 2025-01-03 | — | — | CN | claimed |
| CN-119241378-A | Synthesis method of chloroprocaine hydrochloride intermediate impurity | 南京斯泰尔医药科技有限公司 | 2025-01-03 | — | — | CN | claimed |
| CN-119192013-A | Synthesis method of chloroprocaine hydrochloride impurity | 南京斯泰尔医药科技有限公司 | 2024-12-27 | — | — | CN | claimed |
| CN-119015216-A | Gel type nanometer photosensitizer for local skin surface or cavity and preparation method and application thereof | 镇江华越医疗器械销售有限责任公司 | 2024-11-26 | — | — | CN | claimed |
| CN-118416028-A | Oral mucosa repair film and preparation method and application thereof | 宁波市第二医院 | 2024-08-02 | — | — | CN | claimed |
| WO-1997007793-A1 | FORMULATIONS OF HALOALKYLAMINES AND LOCAL ANAESTHETICS AND METHODS FOR THE TREATMENT OF REFLEX SYMPATHETIC DYSTROPHY (RSD) | NEW YORK MEDICAL COLLEGE (US) | 1997-03-06 | — | — | WO | claimed |
| CN-1137748-A | Gas used as local and subcutaneous transmission carrier and microspheres filled with gas precursor | IMARX PHARMACEUTICAL CORP (US) | 1996-12-11 | — | — | CN | claimed |
| EP-0740528-A1 | GAS MICROSPHERES FOR TOPICAL AND SUBCUTANEOUS APPLICATION | IMARX PHARMACEUTICAL CORP. (US) | 1996-11-06 | — | — | EP | claimed |
| WO-1995034298-A1 | INHIBITION OF INTRAOPERATIVE MIOSIS/PRODUCTION OF MYDRIASIS BY LOCAL ANESTHETICS | TELOR OPHTHALMIC PHARMACEUTICALS, INC. (US) | 1995-12-21 | — | — | WO | claimed |
| WO-1995015118-A1 | GAS MICROSPHERES FOR TOPICAL AND SUBCUTANEOUS APPLICATION | IMARX PHARMACEUTICAL CORP. (US) | 1995-06-08 | — | — | WO | claimed |
| EP-0643964-A2 | Use of local anesthetics for the manufacture of a medicament for the protection of plasma cell membranes | Medipharma S.A. (AR) | 1995-03-22 | — | — | EP | claimed |
| CN-1091317-A | Improve the part input of medicine | PROCTER & GAMBLE (US) | 1994-08-31 | — | — | CN | claimed |
| CN-1079896-A | The compositions of topical aromatic releasing | RICHARDSON VICKS INC (US) | 1993-12-29 | — | — | CN | claimed |
| CN-1072863-A | Be used to improve the dermal osmosis system of the reinforcement of medicine localized delivery | RICHARDSON VICKS INC (US) | 1993-06-09 | — | — | CN | claimed |
| CN-1072602-A | Improve the enhanced dermal osmosis system of the local conveying of medicine | RICHARDSON VICKS INC (US) | 1993-06-02 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097044-A1 | ION PAIR LIQUID CRYSTAL FORMULATIONS FOR LONG-ACTING INJECTABLES OF POORLY SOLUBLE DRUGS | SSB, LTB4R2, THRB | SCN1A 865/4885SCN2A 396/4885SCN3A 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.